Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 19 November 2021

• Date:
  Friday, 19 November 2021
• Location:
  Online
  European Medicines Agency, Amsterdam, the Netherlands

This extraordinary plenary meeting is organised in the context of the Article 5(3) reviews of COVID-19 treatments Lagevrio (molnupiravir) and Paxlovid (PF-07321332 / ritonavir).

The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the European Medicines Agency's opinions on all questions concerning human medicines.